STOCK TITAN

IVVD insider files Form 144 to sell 66,000 shares after RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for Invivyd, Inc. (IVVD): An insider filed a proposed sale of 66,000 shares of Common Stock on Nasdaq with an aggregate market value of $46,668.60, approximately 0.055% of the reported 120,142,811 shares outstanding. The securities were acquired on 08/15/2025 when 165,000 shares vested as restricted stock units under the company's 2021 Equity Incentive Plan, and the sale was slated for 08/18/2025 through Morgan Stanley Smith Barney LLC Executive Financial Services. The filer certifies absence of undisclosed material adverse information and notes no securities sold in the past three months.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small, routine insider sale following RSU vesting; unlikely to be materially market-moving.

The filing reports a planned sale of 66,000 shares acquired via RSU vesting three days earlier. The sale size represents roughly 0.055% of outstanding shares, indicating the transaction is administrative/liquidity-driven rather than a signal of company distress. Broker details and transaction dates are provided, and the filer attests no undisclosed material adverse information. Given the short window between vesting and notice, investors may note insider liquidity but should treat this as routine equity compensation monetization.

TL;DR: Disclosure aligns with Rule 144 requirements; documentation shows RSU vesting and planned brokered sale.

The notice documents acquisition via restricted stock unit vesting under the 2021 Equity Incentive Plan and identifies the executing broker. The filer affirms the absence of material nonpublic information, and there are no reported sales in the prior three months. From a governance perspective, the filing meets procedural norms for insider dispositions under Rule 144 and references potential Rule 10b5-1 considerations, though no plan adoption date is shown.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did Invivyd (IVVD) disclose in the Form 144?

The filing discloses a proposed sale of 66,000 Common Stock shares through Morgan Stanley Smith Barney, with an aggregate market value of $46,668.60 and an approximate sale date of 08/18/2025.

How were the shares being sold acquired?

The shares were acquired on 08/15/2025 upon vesting of restricted stock units granted under Invivyd's 2021 Equity Incentive Plan; 165,000 securities were acquired on that date.

How large is the proposed sale relative to outstanding shares of IVVD?

The proposed 66,000-share sale is about 0.055% of the reported 120,142,811 shares outstanding.

Did the filer report other sales in the past three months?

No; the filing states Nothing to Report for securities sold during the past three months.

Does the filing indicate the filer knows material nonpublic information?

By signing the notice, the person represents they do not know any undisclosed material adverse information regarding the issuer.
Invivyd

NASDAQ:IVVD

IVVD Rankings

IVVD Latest News

IVVD Latest SEC Filings

IVVD Stock Data

688.05M
223.47M
19.2%
60.75%
2.52%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW HAVEN